Research

SEC What Changed
AI, CRCW, CRWS, DAKT, MEI, WLY
Daktronics (DAKT) 10-K: MD&A Changes Lead 24 June 2026 Filing Roundup
Jun 24, 2026
Daktronics (DAKT)’s MD&A section changed the most among 6 companies that filed 10-Ks on 24 June 2026, each compared against its prior-year filing.
Read note
SEC What Changed
BNC, UCLE
CEA Industries (BNC) 10-K: MD&A Changes Lead 23 June 2026 Filing Roundup
Jun 23, 2026
CEA Industries (BNC)’s MD&A section changed the most among 2 companies that filed 10-Ks on 23 June 2026, each compared against its prior-year filing.
Read note
Equity Research
EOSE
Eos Energy Enterprises Stock Analysis: EOSE Cash Burn, Revenue Growth & Financing Risk
Jun 22, 2026
Eos Energy Enterprises (EOSE) is rated Hold as rapid Q1 revenue growth is offset by persistent cash burn and a stretched valuation. The company still posted negative operating and free cash flow, leaving investors dependent on a future margin inflection that has yet to appear.
Read note
SEC What Changed
CASY, ORCL-PD, POWWP, USDW
USDW Stock: Made in USA 10-K Analysis & Growth Thesis
Jun 22, 2026
Made IN USA (USDW)’s Risk Factors section changed the most among 14 companies that filed 10-Ks on 22 June 2026, each compared against its prior-year filing.
Read note
Equity Research
CAR
Avis Budget Stock Analysis: Buy or Sell? Cash Flow, Leverage & Valuation
Jun 21, 2026
Avis Budget Group (CAR) earns a buy rating because strong free cash flow and solid margins still support equity value. The main overhang is heavy debt, with leverage high enough to keep valuation mixed despite robust cash generation.
Read note
Equity Research
BW
Babcock & Wilcox Enterprises Stock Analysis: Valuation, Backlog, Debt Maturity & Cash Flow
Jun 19, 2026
Babcock & Wilcox Enterprises (BW) is rated SELL as a turnaround story with strong backlog but weak earnings power. The key financial concern is negative operating cash flow and a 2026 debt maturity that could force a restructuring if execution slips.
Read note
Equity Research
QXO
QXO Stock Analysis: Valuation, Margins, Free Cash Flow & Leverage
Jun 18, 2026
QXO, Inc. (QXO) is rated Hold as its valuation already prices in a recovery that has yet to show up in earnings. With operating margin still negative and levered free cash flow deeply in the red, the key question is whether the 600-branch platform can finally convert scale into profit.
Read note
Equity Research
AEHR
Aehr Test Systems Stock Analysis: Valuation, Margins, Cash Flow & Customer Risk
Jun 18, 2026
Aehr Test Systems (AEHR) earns a SELL rating as its valuation far outpaces current earnings power. Revenue is falling, cash flow remains negative, and customer concentration adds meaningful execution risk despite a strong balance sheet.
Read note
Equity Research
INCY
Incyte Stock Analysis: Valuation, Patent Cliff, Cash Flow & Growth
Jun 18, 2026
Incyte (INCY) is rated Hold as strong cash generation and reasonable valuation are offset by the looming 2028 JAKAFI patent cliff. The company is profitable, but investors need OPZELURA, ZYNYZ and NIKTIMVO to scale fast enough to replace legacy franchise erosion.
Read note
SEC What Changed
CPBI, ETST, GRCE, JRSH, MDT
Grace Therapeutics (GRCE) 10-K: Business Changes Lead 18 June 2026 Filing Roundup
Jun 18, 2026
Grace Therapeutics (GRCE)’s Business section changed the most among 6 companies that filed 10-Ks on 18 June 2026, each compared against its prior-year filing.
Read note

Waitlist

Join the lf0 premium research waitlist.

More detailed equity research, scorecards, and performance analysis are coming. Add your email to be first in line.

Join the Waitlist